Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

Cancer Medicine

Volumn 5, Issue 8, 2016, Pages 1897-1907

  Peterson, Douglas E ^a   O'Shaughnessy, Joyce A ^b   Rugo, Hope S ^c   Elad, Sharon ^d,e   Schubert, Mark M ^f   Viet, Chi T ^g   Campbell Baird, Cynthia ^h   Hronek, Jan ⁱ   Seery, Virginia ^j   Divers, Josephine ^b   Glaspy, John ^k   Schmidt, Brian L ^g   Meiller, Timothy F ^l  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f SEATTLE CANCER CARE ALLIANCE   (United States)

^g NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^h PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

more..

Author keywords

mTOR inhibitor; oral mucosal injury; oral mucositis; stomatitis

Indexed keywords

ENDOTHELIN 1; EVEROLIMUS; EXEMESTANE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; NERVE GROWTH FACTOR RECEPTOR; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; TUMOR NECROSIS FACTOR;

APHTHOUS STOMATITIS; BACTEROIDALES; CANCER CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HERPETIFORM STOMATITIS; HUMAN; KIDNEY CANCER; METASTATIC BREAST CANCER; MOUTH FLORA; MOUTH PAIN; NONHUMAN; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS;

EID: 85000692373     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.761     Document Type: Review

References (62)

1. Sonis, S. T. 2011. Oral mucositis. Anticancer Drugs 22:607–612.
2. Sonis, S. T. 2013. Oral mucositis in head and neck cancer: risk, biology, and management. Am. Soc. Clin. Oncol. Educ. Book. doi: 10.1200/EdBook_AM.2013.33.e236.
3. Epstein, J. B., J. Thariat, R. J. Bensadoun, A. Barasch, B. A. Murphy, L. Kolnick, et al. 2012. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J. Clin. 62:400–422.
4. Barasch, A., and J. B. Epstein. 2011. Management of cancer therapy-induced oral mucositis. Dermatol. Ther. 24:424–431.
5. Cheng, K. K., V. Lee, C. H. Li, W. Goggins, D. R. Thompson, H. L. Yuen, et al. 2011. Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy. Oral Oncol. 47:153–162.
6. Peterson, D. E., D. M. Keefe, and S. T. Sonis. 2012. New frontiers in mucositis. Am. Soc. Clin. Oncol. Educ. Book 2012:545–551.
7. Boers-Doets, C. B., J. E. Raber-Durlacher, N. S. Treister, J. B. Epstein, A. B. Arends, D. R. Wiersma, et al. 2013. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 9:1883–1892.
8. Peterson, D. E., R. J. Bensadoun, C. Boers-Doets, J. Herrstedt; and ESMO Guidelines Committee. 2015. Management of oral and gastrointestinal mucosal injury ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 26(Suppl 5):v139–v151.
9. Martins, F., M. A. de Oliveira, Q. Wang, S. Sonis, M. Gallottini, S. George, et al. 2013. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 49:293–298.
10. Sonis, S., N. Treister, S. Chawla, G. Demetri, and F. Haluska. 2010. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210–215.
11. Sankhala, K., A. Mita, K. Kelly, D. Mahalingam, F. Giles, and M. Mita. 2009. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 4:135–142.
12. Chavez-MacGregor, M., and A. M. Gonzalez-Angulo. 2012. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin. Investig. Drugs 21:1835–1843.
13. Suzuki, A., R. Kobayashi, S. Okayasu, B. Kuze, M. Aoki, K. Mizuta, et al. 2014. Pharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: a single arm intervention study. PLoS ONE 9:e115879.
14. Villa, A., A. Aboalela, K. A. Luskin, C. S. Cutler, S. T. Sonis, S. B. Woo, et al. 2015. Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. Biol. Blood Marrow Transplant. 21:503–508.
15. Abdel-Rahman, O., and M. Fouad. 2014. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Expert Rev. Anticancer Ther. 14:751–760.
16. Yardley, D. A. 2014. Adverse event management of mtor inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. Clin. Breast Cancer 14:297–308.
17. Divers, J., and J. O'Shaughnessy. 2015. Stomatitis associated with use of mtor inhibitors: implications for patients with invasive breast cancer. Clin. J. Oncol. Nurs. 19:468–474.
18. Meiller, T. F., S. Varlotta, and D. Weikel. 2015. Recognition and management of oral mucosal injury caused by mammalian target of rapamycin inhibitors: a case series. Case Rep. Oncol. 8:369–377.
19. Watters, A. L., J. B. Epstein, and M. Agulnik. 2011. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 47:441–448.
20. Novartis Pharmaceuticals Corporation. 2014. Afinitor (everolimus tablets for oral administration). Afinitor Disperz (everolimus tablets for oral suspension) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
21. Pfizer. 2012. Torisel Kit (temsirolimus) injection, for intravenous infusion only [package insert]. Pfizer, Philadelphia, PA.
22. Morgenstern, D. A., M. Marzouki, U. Bartels, M. S. Irwin, G. L. Sholler, J. Gammon, et al. 2014. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr. Blood Cancer 61:128–133.
23. Al-Dasooqi, N., S. T. Sonis, J. M. Bowen, E. Bateman, N. Blijlevens, R. J. Gibson, et al. 2013. Emerging evidence on the pathobiology of mucositis. Support. Care Cancer 21:2075–2083.
24. Sonis, S. T. 1998. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34:39–43.
25. Talwar, S., R. House, S. Sundaramurthy, S. Balasubramanian, H. Yu, and V. Palanisamy. 2014. Inhibition of caspases protects mice from radiation induced oral mucositis and abolishes the cleavage of RNA binding protein HuR. J. Biol. Chem. 289:3487–3500.
26. Wardill, H. R., J. M. Bowen, N. Al-Dasooqi, M. Sultani, E. Bateman, R. Stansborough, et al. 2014. Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biol. Ther. 15:236–244.
27. Mougeot, J. L., F. K. Mougeot, D. E. Peterson, R. J. Padilla, M. T. Brennan, and P. B. Lockhart. 2013. Use of archived biopsy specimens to study gene expression in oral mucosa from chemotherapy-treated cancer patients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 115:630–637.
28. Katholnig, K., M. Linke, H. Pham, M. Hengstschlager, and T. Weichhart. 2013. Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem. Soc. Trans. 41:927–933.
29. Lewkowicz, N., P. Lewkowicz, K. Dzitko, B. Kur, M. Tarkowski, A. Kurnatowska, et al. 2008. Dysfunction of CD4+ CD25high T regulatory cells in patients with recurrent aphthous stomatitis. J. Oral Pathol. Med. 37:454–461.
30. Bankvall, M., F. Sjoberg, G. Gale, A. Wold, M. Jontell, and S. Ostman. 2014. The oral microbiota of patients with recurrent aphthous stomatitis. J. Oral Microbiol. 6:25739.
31. Hijazi, K., T. Lowe, C. Meharg, S. H. Berry, J. Foley, and G. L. Hold. 2015. Mucosal microbiome in patients with recurrent aphthous stomatitis. J. Dent. Res. 94:87S–94S.
32. Koybasi, S., A. H. Parlak, E. Serin, F. Yilmaz, and D. Serin. 2006. Recurrent aphthous stomatitis: investigation of possible etiologic factors. Am. J. Otolaryngol. 27:229–232.
33. Chen, H., Q. Sui, Y. Chen, L. Ge, and M. Lin. 2015. Impact of haematologic deficiencies on recurrent aphthous ulceration: a meta-analysis. Br. Dent. J. 218:E8.
34. Kozlak, S. T., S. J. Walsh, and R. V. Lalla. 2010. Reduced dietary intake of vitamin B12 and folate in patients with recurrent aphthous stomatitis. J. Oral Pathol. Med. 39:420–423.
35. Slebioda, Z., E. Szponar, and A. Kowalska. 2013. Recurrent aphthous stomatitis: genetic aspects of etiology. Postepy. Dermatol. Alergol. 30:96–102.
36. Karasneh, J., M. Bani-Hani, A. Alkhateeb, A. Hassan, F. Alzoubi, and M. Thornhill. 2014. TLR2, TLR4 and CD86 gene polymorphisms in recurrent aphthous stomatitis. J. Oral Pathol. Med. 44:857–863.
37. Sessa, C., D. Tosi, L. Vigano, J. Albanell, D. Hess, M. Maur, et al. 2010. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann. Oncol. 21:1315–1322.
38. Scully, C. 2006. Clinical practice. Aphthous ulceration. N. Engl. J. Med. 355:165–172.
39. Elting, L. S., D. M. Keefe, S. T. Sonis, A. S. Garden, F. K. Spijkervet, A. Barasch, et al. 2008. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113:2704–2713.
40. Viet, C. T., P. M. Corby, A. Akinwande, and B. L. Schmidt. 2014. Review of preclinical studies on treatment of mucositis and associated pain. J. Dent. Res. 93:868–875.
41. McMahon, S., M. Koltzenburg, I. Tracey, and D. C. Turk. 2011. Wall & Melzack's textbook of pain, 6th ed. WB Saunders Co, St Louis, MO.
42. Sonis, S. T. 2004. The pathobiology of mucositis. Nat. Rev. Cancer 4:277–284.
43. US Department of Health and Human Services. 2010. Common terminology criteria for adverse events (CTCAE), v4.03. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. June 14, 2010. (accessed 19 June 2015).
44. Boers-Doets, C., and R. V. Lalla. 2013. The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis. Supp. Care Cancer 21(Suppl. 1):1–6 Abstract MASCC-0396.
45. Rugo, H. S., K. I. Pritchard, M. Gnant, S. Noguchi, M. Piccart, G. Hortobagyi, et al. 2014. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann. Oncol. 25:808–815.
46. Porta, C., S. Ostanto, A. Ravaud, M. A. Climent, U. Vaishampayan, D. A. White, et al. 2011. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47:1287–1298.
47. Pilotte, A. P., M. B. Hohos, K. M. Polson, T. M. Huftalen, and N. Treister. 2011. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin. J. Oncol. Nurs. 15:E83–E89.
48. de Oliveira, M. A., E. M. F. Martins, Q. Wang, S. Sonis, G. Demetri, S. George, et al. 2011. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol. 47:998–1003.
49. Kalogirou, E. M., K. I. Tosios, E. P. Piperi, and A. Sklavounou. 2015. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 119:e13–e19.
50. Chuang, P., and A. J. Langone. 2007. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am. J. Transplant. 7:714–717.
51. Raymond, E., J. Alexandre, S. Faivre, K. Vera, E. Materman, J. Boni, et al. 2004. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22:2336–2347.
52. Ferte, C., A. Paci, M. Zizi, D. B. Gonzales, A. Goubar, C. Gomez-Roca, et al. 2011. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur. J. Cancer 47:2249–2255.
53. Rubenstein, E. B., D. E. Peterson, M. Schubert, D. Keefe, D. McGuire, J. Epstein, et al. 2004. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046.
54. Keefe, D. M., M. M. Schubert, L. S. Elting, S. T. Sonis, J. B. Epstein, J. E. Raber-Durlacher, et al. 2007. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831.
55. Lalla, R. V. 2013. The MASCC/ISOO mucositis guidelines update: introduction to the first set of articles. Support. Care Cancer 21:301–302.
56. Peterson, D., R. Srivastava, and R. Lalla. 2015. Oral mucosal injury in oncology patients: perspectives on maturation of a field. Oral Dis. 21:133–141.
57. Jensen, S. B., and D. E. Peterson. 2014. Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. J. Oral Pathol. Med. 43:81–90.
58. Hahn, T., E. Zhelnova, L. Sucheston, I. Demidova, V. Savchenko, M. Battiwalla, et al. 2010. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol. Blood Marrow Transplant. 16:801–808.
59. Sonis, S. T., J. H. Antin, M. W. Tedaldi, and G. Alterovitz. 2013. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis. 19:721–727.
60. US Oncology Research. 2000. Miracle mouthwash plus hydrocortisone vs prednisolone mouth rinse for mouth sores caused by everolimus. In: ClinicalTrials.gov. National Library of Medicine (US), Bethesda (MD). Available at: https://clinicaltrials.gov/ct2/show/NCT02229136 NLM Identifier: NCT02229136 (accessed 21 September 2015).
61. Novartis Pharmaceuticals. 2000. Open-label, phase II study of stomatitis prevention with a steroid-based mouthwash in post-menopausal women with ER+, HER2- metastatic or locally advanced breast cancer. In: ClinicalTrials.gov. National Library of Medicine (US), Bethesda (MD). Available at: https://clinicaltrials.gov/ct2/show/NCT02069093 NLM Identifier: NCT02069093 (accessed 21 September 2015).
62. Sonis, S. T. 2009. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 45:1015–1020.